Stay updated on Nivolumab+Brentuximab Post-SCT in Hodgkin Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab+Brentuximab Post-SCT in Hodgkin Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab+Brentuximab Post-SCT in Hodgkin Lymphoma Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    Revision: v3.5.5 was added, replacing v3.5.4. This reflects a page revision update and does not change the study details or results.
    Difference
    0.0%
    Check dated 2026-06-08T04:30:26.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    No Change Detected
  4. Check
    23 days ago
    Change Detected
    Summary
    Revision: v3.5.4 replaces the previous v3.5.3, indicating an updated page build without changes to displayed content.
    Difference
    0.0%
    Check dated 2026-05-17T10:14:25.000Z thumbnail image
  5. Check
    38 days ago
    Change Detected
    Summary
    The study record dates have been updated to include new entries (2026-05-01, 2027-02-25, 2026-04-17, 2026-04) and remove earlier entries (2025-05-07, 2026-03-25, 2025-04-29, 2025-04), reflecting adjustments to the posting and QC timeline on the page.
    Difference
    0.2%
    Check dated 2026-05-03T01:20:23.000Z thumbnail image
  6. Check
    45 days ago
    Change Detected
    Summary
    The page version/build indicator was updated from v3.5.2 to v3.5.3, reflecting a minor administrative release rather than a substantive change to the trial’s study details.
    Difference
    0.0%
    Check dated 2026-04-25T18:39:53.000Z thumbnail image
  7. Check
    52 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2.
    Difference
    0.0%
    Check dated 2026-04-18T13:33:58.000Z thumbnail image
  8. Check
    81 days ago
    Change Detected
    Summary
    - Updated page revision from v3.4.3 to v3.5.0. This appears to be an administrative update and does not modify study details or eligibility criteria.
    Difference
    0.0%
    Check dated 2026-03-21T01:21:18.000Z thumbnail image

Stay in the know with updates to Nivolumab+Brentuximab Post-SCT in Hodgkin Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab+Brentuximab Post-SCT in Hodgkin Lymphoma Clinical Trial page.